The Maternal Lifestyle Study: Drug exposure during pregnancy and short-term maternal outcomes

Charles R. Bauer, Seetha Shankaran, Henrietta S. Bada, Barry Lester, Linda L. Wright, Heidi Krause-Steinrauf, Vincent L. Smeriglio, Loretta P. Finnegan, Penelope L. Maza, Joel Verter

Research output: Contribution to journalArticlepeer-review

169 Scopus citations

Abstract

OBJECTIVE: Reports of maternal effects resulting from drug exposure during pregnancy are inconsistent. The Maternal Lifestyle Study (MLS) is a multicenter, prospective, observational study that was initiated to better define the effects of exposure to illicit drugs during pregnancy on the mother, fetus, and infant. METHODS: Between May 1993 and May 1995, of 19,079 mother-infant dyads that were screened after delivery for cocaine and opiate exposure at four clinical centers (Brown University, University of Miami, University of Tennessee, Memphis, and Wayne State University), 16,988 (89%) met eligibility criteria and 11,811 (70%) of those eligible agreed to participate in the study. Exposure was defined as an admission of use of cocaine or opiates or both or the presence of cocaine or opiate metabolites in meconium as determined by use of gas chromatography-mass spectroscopy assay. Nonexposure was defined as a negative drug use history by interview and a negative immunoassay screen. When exposure could not be confirmed, such as when meconium was not obtained or was inadequate for confirmatory analysis, the mother-infant dyad was excluded (n = 3184). RESULTS: Of the mothers who consented to participate, 50% were African American, 38% were married, 64% were Medicaid recipients, and 95% had at least one prenatal care visit (median, 10 visits). Significant differences (P < .01) between cocaine-opiate exposed (n = 1185) and nonexposed (n = 7442) mothers included race (African American: 74.6% and 47.0%, respectively), mean age (29.6 and 26.1 years, respectively), and polydrug use including any combination of alcohol, tobacco, and/or marijuana (93% and 42%, respectively). Odds ratios (99% CI) indicate that exposed mothers had a significantly higher risk (P < .001) of medical complications including syphilis 6.7 (4.8-9.6), gonorrhea 1.9 (1.3-3.0), and hepatitis 4.8 (2.6-8.91); psychiatric, nervous, and emotional disorders 4.0 (2.2-7.4); and abruptio placenta 2.3 (1.4-3.9). The odds of a positive test for human immunodeficiency virus were higher (available on 28% of the cohort) in the exposed group 8.2 (14.3-15.4). Seventeen cases of maternal acquired immunodeficiency syndrome (AIDS) were identified. Opiate exposure with its attendant needle use significantly increased the risk of hepatitis and AIDS. The number of hospitalizations during pregnancy did not differ between the exposure groups because ∼ 11% of patients in each group were hospitalized at least once. However, violence as a cause of hospitalization was more common in the cocaine-exposed group, 19.6 (2.7-144.7). CONCLUSION: This observational study confirmed many of the reported adverse social and serious medical perinatal complications of mothers exposed to cocaine or opiates during pregnancy. The overall prevalence of these risk outcomes was lower than has been reported previously.

Original languageEnglish
Pages (from-to)487-495
Number of pages9
JournalAmerican Journal of Obstetrics and Gynecology
Volume186
Issue number3
DOIs
StatePublished - 2002

Bibliographical note

Funding Information:
Supported by the National Institute of Child Health and Human Development through cooperative agreements (No. U10 HD 21397), a (No. U10 HD 21385), b (No. U10 HD 27856), c (No. U10 HD 27904), d and (No. U01 HD 19897), f and intra-agency agreements with the National Institute on Drug Abuse, Administration on Children, Youth and Families, and the Center for Substance Abuse Treatment. (CSAT)

Funding

Supported by the National Institute of Child Health and Human Development through cooperative agreements (No. U10 HD 21397), a (No. U10 HD 21385), b (No. U10 HD 27856), c (No. U10 HD 27904), d and (No. U01 HD 19897), f and intra-agency agreements with the National Institute on Drug Abuse, Administration on Children, Youth and Families, and the Center for Substance Abuse Treatment. (CSAT)

FundersFunder number
National Institute on Drug Abuse
Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentU10 HD 27904, U01 HD 19897, U10 HD 27856, U10 HD 21385, U10 HD 21397
Administration for Children and Families
Center for Substance Abuse Treatment

    Keywords

    • Alcohol
    • Cocaine
    • Drug abuse
    • Drug use
    • Fetus
    • Marijuana
    • Maternal medical/health outcomes
    • NICHD Neonatal Research Network
    • Newborn
    • Opiates
    • Perinatal
    • Polydrug use
    • Pregnancy
    • Tobacco

    ASJC Scopus subject areas

    • Obstetrics and Gynecology

    Fingerprint

    Dive into the research topics of 'The Maternal Lifestyle Study: Drug exposure during pregnancy and short-term maternal outcomes'. Together they form a unique fingerprint.

    Cite this